Dividends - The board proposed a final dividend of HKD 0.06 per share and a special dividend of HKD 0.03 per share for the year ending December 31, 2022, subject to shareholder approval at the annual general meeting on May 18, 2023[1]. - The total proposed dividends amount to HKD 68,009,000, with HKD 45,339,000 for the final dividend and HKD 22,670,000 for the special dividend[14]. - The company declared a total dividend of HKD 0.09 per share, which includes a special dividend of HKD 0.03[27]. - The group will pay dividends in Hong Kong dollars in the future, and any significant fluctuations in the exchange rate may impact financial results[187]. Financial Performance - The group's revenue for the year ended December 31, 2022, was RMB 1,825,935 thousand, representing a 4.5% increase from RMB 1,746,500 thousand in 2021[27]. - Gross profit for the same period was RMB 1,072,295 thousand, with a gross margin of 58.7%, down from 60.8% in the previous year[27]. - Net profit attributable to equity holders was RMB 106,387 thousand, a significant increase of 104.1% compared to RMB 52,128 thousand in 2021[27]. - The pre-tax profit for the group was RMB 332,371,000, a decrease of 3.1% compared to RMB 343,093,000 in 2021[10]. - The total comprehensive income for the year was RMB 104,764 thousand, compared to RMB 53,147 thousand in 2021[31]. - The income tax expense for the year was RMB 23,736 thousand, compared to RMB 9,447 thousand in 2021[34]. - The group reported other income and gains of RMB 33,700 thousand, up from RMB 29,771 thousand in the previous year[34]. - The group reported external customer revenue of RMB 717,950,000 for the segment, with inter-segment sales amounting to RMB 1,129,905,000[70]. - Total revenue for the group reached RMB 1,825,935,000, with a pre-tax profit of RMB 130,651,000[70]. Research and Development - The group's research and development costs for the year amounted to RMB 46,350,000, up from RMB 43,834,000 in 2021, reflecting a growth of 3.7%[10]. - Research and development expenses increased to approximately RMB 46.4 million, up about 5.7% from 43.8 million in the previous year[152]. Assets and Liabilities - The company's total assets increased to RMB 1,005,949 thousand from RMB 901,165 thousand in the previous year[37]. - Non-current assets total RMB 784,337 thousand, an increase from RMB 666,668 thousand year-on-year[49]. - Current assets amount to RMB 1,090,920 thousand, up from RMB 857,437 thousand compared to the previous year[49]. - Total liabilities increased to RMB 731,251 thousand from RMB 500,831 thousand year-on-year[49]. - The group reported a net asset value of RMB 359,669 thousand, slightly up from RMB 356,606 thousand year-on-year[49]. - As of December 31, 2022, the equity attributable to shareholders was approximately RMB 1,005.9 million, compared to RMB 901.2 million the previous year[182]. Expenses - The group incurred sales and distribution expenses of RMB 829,237,000, alongside administrative expenses of RMB 104,746,000[71]. - Selling and distribution expenses decreased by approximately 2.3% to RMB 809.8 million, representing about 44.4% of revenue[178]. - Administrative expenses increased by approximately 1.8% to RMB 104.7 million due to increased depreciation and office expenses[178]. - The company's financing costs for the year were RMB 7,080,000, which is a part of the overall administrative expenses totaling RMB 102,899,000[86]. Customer and Credit Management - The company has no single customer contributing more than 10% of total sales revenue, indicating a diversified customer base[84]. - The company maintains strict control over its trade receivables, with overdue balances regularly reviewed by senior management to mitigate credit risk[132]. - The expected credit loss rate for the year was 1.69%, with total expected credit losses amounting to RMB 3,387 thousand[136]. - The company has no significant credit concentration risk due to a diverse customer base with a good historical record, ensuring a low expected credit loss rate for trade receivables and notes receivable[132]. Future Outlook - Future outlook includes continued focus on expanding market presence and enhancing product offerings, although specific numerical guidance was not provided in the call[117]. - The group believes that existing financial resources and funds from business operations will provide sufficient capital for future expansion plans[184]. Compliance and Governance - The group has adopted and complied with the corporate governance code as per the listing rules during the reporting period[194]. - The financial statements are prepared in accordance with International Financial Reporting Standards and reflect historical cost conventions[52]. Changes in Operations - The group operates primarily in the manufacturing and sales of pharmaceutical products in China[51]. - The group has not undergone any significant changes in its main activities during the year[51]. - The group has restructured its internal organization, resulting in a change in reportable segments, now comprising pharmaceutical and retail pharmacy operations[66].
中智药业(03737) - 2022 - 年度业绩